{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:12:31Z","timestamp":1788797551772,"version":"build-2803163510"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Vitamin K antagonists (VKAs) are highly effective but have a narrow therapeutic index and require routine monitoring of the INR. The primary aim of pharmacogenetics (PGx) is to optimize patient care, achieving drug treatments that are personalized according to the genetic profile of each patient. The best-characterized genes involved in VKA PGx involve pharmacokinetics (\n                      <jats:italic toggle=\"yes\">VKORC1<\/jats:italic>\n                      ) and pharmacodynamics (\n                      <jats:italic toggle=\"yes\">CYP2C9<\/jats:italic>\n                      ) of VKA metabolism. The role of these genes in clinical outcomes (bleeding and thrombosis) during oral anticoagulant (OAC) therapy is controversial. The aim of the present study was to evaluate any potential association between genotype\n                      <jats:italic toggle=\"yes\">VKORC1<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">CYP2C9<\/jats:italic>\n                      and adverse events (hemorrhagic and\/or thrombotic), during initiation and long-term VKA treatment, in Caucasian patients. Furthermore, we aimed to determine if the concomitant prescription of other selected drugs affected the association between genotype and adverse events.\n                    <\/jats:p>\n                    <jats:p>We performed a retrospective, matched case-control study to determine associations between multiple gene variants, drug intake, and any major adverse effects in anticoagulated patients, monitored in 2 Italian anticoagulation clinics.<\/jats:p>\n                    <jats:p>\n                      Our results show that anticoagulated patients have a high risk of adverse events if they are carriers of 1 or more genetic polymorphisms in the\n                      <jats:italic toggle=\"yes\">VKORC1<\/jats:italic>\n                      (rs9923231) and\n                      <jats:italic toggle=\"yes\">CYP2C9<\/jats:italic>\n                      (rs1799853 and rs1057910) genes.\n                    <\/jats:p>\n                    <jats:p>\n                      Information on\n                      <jats:italic toggle=\"yes\">CYP2C9<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">VKORC1<\/jats:italic>\n                      variants may be useful to identify individualized oral anticoagulant treatment for each patient, improve management and quality of VKA anticoagulation control, and monitor drug surveillance in pharmacovigilance programs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000005451","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T14:06:09Z","timestamp":1483020369000},"page":"e5451","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients"],"prefix":"10.1097","volume":"95","author":[{"given":"Silvia","family":"Misasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Calza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scovoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Marengoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Marchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20260907","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"R2-3-20260907","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fcvm.2015.00030","article-title":"Anticoagulant treatment of deep vein thrombosis and pulmonary embolism: the present state of the art","volume":"2","author":"Thaler","year":"2015","journal-title":"Front Cardiovasc Medicine"},{"key":"R4-3-20260907","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tcm.2014.09.001","article-title":"Warfarin pharmacogenetics","volume":"25","author":"Johnson","year":"2015","journal-title":"Trends Cardiovas Med"},{"key":"R5-3-20260907","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tips.2015.01.003","article-title":"Oral anticoagulation: a critique of recent advances and controversies","volume":"36","author":"Pirmohamed","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"R6-3-20260907","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"key":"R7-3-20260907","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature02254","article-title":"Identification of the gene for vitamin K epoxide reductase","volume":"427","author":"Li","year":"2004","journal-title":"Nature"},{"key":"R8-3-20260907","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2","volume":"427","author":"Rost","year":"2004","journal-title":"Nature"},{"key":"R9-3-20260907","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/ars.2006.8.347","article-title":"Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle","volume":"8","author":"Oldenburg","year":"2006","journal-title":"Antioxid Redox Signal"},{"key":"R10-3-20260907","first-page":"236","article-title":"Structural and functional insights into enzymes of the vitamin K cycle","volume":"14","author":"Tie","year":"2016","journal-title":"JTH"},{"key":"R11-3-20260907","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"Rieder","year":"2005","journal-title":"NEJM"},{"key":"R12-3-20260907","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/hmg\/ddi180","article-title":"A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity","volume":"14","author":"Yuan","year":"2005","journal-title":"Hum Mol Gen"},{"key":"R13-3-20260907","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature01862","article-title":"Crystal structure of human cytochrome P450 2C9 with bound warfarin","volume":"424","author":"Williams","year":"2003","journal-title":"Nature"},{"key":"R14-3-20260907","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/FPC.0b013e3283349e84","article-title":"Cytochrome P450 2C9-CYP2C9","volume":"20","author":"Van Booven","year":"2010","journal-title":"Pharmacogenet Genom"},{"key":"R15-3-20260907","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-008-0584-5","article-title":"Influence of CYP2C9 genotype on warfarin dose requirements\u2014a systematic review and meta-analysis","volume":"65","author":"Lindh","year":"2009","journal-title":"Euro J Clin Pharmacol"},{"key":"R16-3-20260907","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00228-010-0809-2","article-title":"VKORC1-1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement","volume":"66","author":"Puehringer","year":"2010","journal-title":"Euro J Clin Pharmacol"},{"key":"R18-3-20260907","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"NEJM"},{"key":"R19-3-20260907","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa1310669","article-title":"A pharmacogenetic versus a clinical algorithm for warfarin dosing","volume":"369","author":"Kimmel","year":"2013","journal-title":"NEJM"},{"key":"R20-3-20260907","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","article-title":"A randomized trial of genotype-guided dosing of warfarin","volume":"369","author":"Pirmohamed","year":"2013","journal-title":"NEJM"},{"key":"R21-3-20260907","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.thromres.2015.01.018","article-title":"Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials","volume":"135","author":"Li","year":"2015","journal-title":"Thromb Res"},{"key":"R22-3-20260907","first-page":"1763","article-title":"Genotype-guided dosing of vitamin K antagonists","volume":"370","author":"Cavallari","year":"2014","journal-title":"NEJM"},{"key":"R23-3-20260907","first-page":"1762","article-title":"Genotype-guided dosing of vitamin K antagonists","volume":"370","author":"Daneshjou","year":"2014","journal-title":"NEJM"},{"key":"R24-3-20260907","first-page":"1763","article-title":"Genotype-guided dosing of vitamin K antagonists","volume":"370","author":"Kimmel","year":"2014","journal-title":"NEJM"},{"key":"R25-3-20260907","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMc1402521","article-title":"Genotype-guided dosing of vitamin K antagonists","volume":"370","author":"Koller","year":"2014","journal-title":"NEJM"},{"key":"R26-3-20260907","first-page":"1765","article-title":"Genotype-guided dosing of vitamin K antagonists","volume":"370","author":"Maitland-van der Zee","year":"2014","journal-title":"NEJM"},{"key":"R27-3-20260907","first-page":"1762","article-title":"Genotype-guided dosing of vitamin K antagonists","volume":"370","author":"Pereira","year":"2014","journal-title":"NEJM"},{"key":"R28-3-20260907","first-page":"1764","article-title":"Genotype-guided dosing of vitamin K antagonists","volume":"370","author":"Pirmohamed","year":"2014","journal-title":"NEJM"},{"key":"R29-3-20260907","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMc1402521","article-title":"Genotype-guided dosing of vitamin K antagonists","volume":"370","author":"Schwarz","year":"2014","journal-title":"NEJM"},{"key":"R30-3-20260907","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ijcard.2014.06.031","article-title":"Outcomes of pharmacogenetics-guided dosing of warfarin: a systematic review and meta-analysis","volume":"175","author":"Tang","year":"2014","journal-title":"Int J Cardiol"},{"key":"R31-3-20260907","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1016\/j.ijcard.2013.07.151","article-title":"Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis","volume":"168","author":"Yang","year":"2013","journal-title":"Int J Cardiol"},{"key":"R32-3-20260907","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jamainternmed.2014.2368","article-title":"Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials","volume":"174","author":"Stergiopoulos","year":"2014","journal-title":"JAMA Int Med"},{"key":"R34-3-20260907","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/FTD.0000000000000192","article-title":"Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy","volume":"37","author":"Shaw","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R35-3-20260907","doi-asserted-by":"crossref","first-page":"e44064","DOI":"10.1371\/journal.pone.0044064","article-title":"Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis","volume":"7","author":"Jorgensen","year":"2012","journal-title":"PloS One"},{"key":"R36-3-20260907","first-page":"636","article-title":"Genetic risk factors for major bleeding in patients treated with warfarin in a community setting","volume":"95","author":"Roth","year":"2014","journal-title":"CPT"},{"key":"R37-3-20260907","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(14)61994-2","article-title":"Genetics and the clinical response to warfarin and edoxaban: findings from the randomized, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"R38-3-20260907","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000350407","article-title":"The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes","volume":"125","author":"Tomek","year":"2013","journal-title":"Cardiology"},{"key":"R39-3-20260907","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2217\/pgs.14.153","article-title":"Genotype and risk of major bleeding during warfarin treatment","volume":"15","author":"Kawai","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R40-3-20260907","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12031-014-0259-x","article-title":"Association between VKORC1 gene polymorphisms and ischemic cerebrovascular disease in Chinese Han population","volume":"53","author":"Zhang","year":"2014","journal-title":"J Mol Neurosci"},{"key":"R41-3-20260907","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/CIRCULATIONAHA.105.580167","article-title":"VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection)","volume":"113","author":"Wang","year":"2006","journal-title":"Circulation"},{"key":"R42-3-20260907","doi-asserted-by":"crossref","first-page":"376","DOI":"10.18553\/jmcp.2014.20.4.376","article-title":"Simultaneous use of amiodarone influences warfarin maintenance dose but is not associated with adverse events","volume":"20","author":"Santos","year":"2014","journal-title":"JMCP"},{"key":"R43-3-20260907","first-page":"e002587","article-title":"Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 trial","volume":"5","author":"Xu","year":"2016","journal-title":"JAMA"},{"key":"R44-3-20260907","first-page":"1422","article-title":"The impact of simvastatin on warfarin disposition and dose requirements","volume":"4","author":"Sconce","year":"2006","journal-title":"JTH"},{"key":"R45-3-20260907","first-page":"369.e369","article-title":"Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin?","volume":"120","author":"Douketis","year":"2007","journal-title":"AMJ"},{"key":"R46-3-20260907","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjmed.2009.07.020","article-title":"Fibrate\/statin initiation in warfarin users and gastrointestinal bleeding risk","volume":"123","author":"Schelleman","year":"2010","journal-title":"AMJ"},{"key":"R47-3-20260907","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2217\/pgs.15.64","article-title":"Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis","volume":"16","author":"You","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R49-3-20260907","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/14740338.2012.631910","article-title":"Epidemiology and characteristics of adverse drug reactions caused by drug\u2013drug interactions","volume":"11","author":"Magro","year":"2012","journal-title":"EODS"},{"key":"R50-3-20260907","first-page":"489","article-title":"Hospital admissions\/visits associated with drug-drug interactions: a systematic review and meta-analysis","volume":"23","author":"Dechanont","year":"2014","journal-title":"PDS"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005792-201612300-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:03:30Z","timestamp":1788797010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201612300-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":46,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005451","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}